公开(公告)号：US11149002B2

公开(公告)日：2021-10-19

申请号：US16702286

申请日：2019-12-03

申请人： GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

发明人： Jean-Christophe Andrez ,  Philippe Bergeron ,  Paul Robert Bichler ,  Sultan Chowdhury ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Wei Gong ,  Michael Edward Grimwood ,  Abid Hasan ,  Ivan William Hemeon ,  Qi Jia ,  Brian Salvatore Safina ,  Shaoyi Sun ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC分类号： C07D207/16 ,  C07D403/12 ,  C07D413/14 ,  C07D221/22 ,  C07D401/12 ,  C07D413/12 ,  C07C235/52 ,  C07D205/04 ,  C07D277/06 ,  C07D209/02 ,  C07D305/08 ,  C07D401/14 ,  C07D231/06 ,  C07D403/04 ,  C07D403/14 ,  C07D409/06 ,  C07D417/12 ,  C07D451/02 ,  C07D263/04 ,  C07D263/26 ,  C07C235/42 ,  C07C235/54 ,  C07D265/30 ,  C07D207/08 ,  C07D207/10 ,  C07D207/22 ,  C07D209/52 ,  C07D209/54 ,  C07D211/20 ,  C07D211/38 ,  C07D211/60 ,  C07D213/69 ,  C07D401/10 ,  C07D405/10 ,  C07D471/08

摘要： The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US10526285B2

公开(公告)日：2020-01-07

申请号：US16150070

申请日：2018-10-02

申请人： GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

发明人： Jean-Christophe Andrez ,  Philippe Bergeron ,  Paul Robert Bichler ,  Sultan Chowdhury ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Wei Gong ,  Michael Edward Grimwood ,  Abid Hasan ,  Ivan William Hemeon ,  Qi Jia ,  Brian Salvatore Safina ,  Shaoyi Sun ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC分类号： C07D207/16 ,  C07D403/12 ,  C07D413/14 ,  C07D221/22 ,  C07D401/12 ,  C07D413/12 ,  C07C235/52 ,  C07D205/04 ,  C07D277/06 ,  C07D209/02 ,  C07D305/08 ,  C07D401/14 ,  C07D231/06 ,  C07D403/04 ,  C07D403/14 ,  C07D409/06 ,  C07D417/12 ,  C07D451/02 ,  C07D263/04 ,  C07D263/26 ,  C07C235/42 ,  C07C235/54 ,  C07D265/30 ,  C07D207/08 ,  C07D207/10 ,  C07D207/22 ,  C07D209/52 ,  C07D209/54 ,  C07D211/20 ,  C07D211/38 ,  C07D211/60 ,  C07D213/69 ,  C07D401/10 ,  C07D405/10 ,  C07D471/08

摘要： The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US10179767B2

公开(公告)日：2019-01-15

申请号：US15161085

申请日：2016-05-20

申请人： GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

发明人： Sultan Chowdhury ,  Christoph Martin Dehnhardt ,  Abid Hasan ,  Ivan William Hemeon ,  Qi Jia ,  Jun Li ,  Zhiguo Liu ,  Daniel F. Ortwine ,  Brian Safina ,  Daniel Sutherlin ,  Shaoyi Sun ,  Andrew D. White ,  Wei Gong ,  Alla Yurevna Zenova ,  Jiuxiang Zhu

IPC分类号： A01N43/00 ,  A61K31/00 ,  C07D211/22 ,  C07D211/48 ,  C07D211/34 ,  C07D405/08 ,  C07D401/12 ,  C07D401/08 ,  C07D211/42 ,  C07D221/20 ,  C07D401/04 ,  C07D211/38 ,  C07D211/62

摘要： The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated with the mediation of sodium channels, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US10125098B2

公开(公告)日：2018-11-13

申请号：US15988956

申请日：2018-05-24

申请人： GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

发明人： Jean-Christophe Andrez ,  Philippe Bergeron ,  Paul Robert Bichler ,  Sultan Chowdhury ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Wei Gong ,  Michael Edward Grimwood ,  Abid Hasan ,  Ivan William Hemeon ,  Qi Jia ,  Brian Safina ,  Shaoyi Sun ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC分类号： C07D207/16 ,  C07D277/06 ,  C07D413/14 ,  C07D413/12 ,  C07D401/10 ,  C07D401/12 ,  C07C235/54 ,  C07D405/10 ,  C07D403/14 ,  C07D471/08

摘要： The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US10005724B2

公开(公告)日：2018-06-26

申请号：US15321335

申请日：2015-07-07

申请人： GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

发明人： Jean-Christophe Andrez ,  Philippe Bergeron ,  Paul Robert Bichler ,  Sultan Chowdhury ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Wei Gong ,  Michael Edward Grimwood ,  Abid Hasan ,  Ivan William Hemeon ,  Qi Jia ,  Brian Safina ,  Shaoyi Sun ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC分类号： C07C235/54 ,  C07D207/16 ,  C07D405/10 ,  C07D401/12 ,  C07D471/08 ,  C07D403/14 ,  C07D401/10 ,  C07D413/12 ,  C07D413/14 ,  C07D277/06

CPC分类号： C07D207/16 ,  C07C235/42 ,  C07C235/52 ,  C07C235/54 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2603/74 ,  C07D205/04 ,  C07D207/08 ,  C07D207/10 ,  C07D207/22 ,  C07D209/02 ,  C07D209/52 ,  C07D209/54 ,  C07D211/20 ,  C07D211/38 ,  C07D211/60 ,  C07D213/69 ,  C07D221/22 ,  C07D231/06 ,  C07D263/04 ,  C07D263/26 ,  C07D265/30 ,  C07D277/06 ,  C07D305/08 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/10 ,  C07D409/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D451/02 ,  C07D471/08

摘要： The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US20240101531A1

公开(公告)日：2024-03-28

申请号：US18330100

申请日：2023-06-06

申请人： Xenon Pharmaceuticals Inc.

发明人： Paul Scott Charifson ,  Christoph Martin Dehnhardt ,  Julien A. Delbrouck ,  Thilo Focken ,  Wei Gong ,  Shawn Johnstone ,  Xiangyu Li ,  Jia Yi Mo ,  Juliette Sabbatani ,  Hong Wang ,  Steven Sigmund Wesolowski ,  Alla Yurevna Zenova ,  Wei Zhang

IPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D495/04 ,  C07D513/04 ,  C07D471/04 ,  C07D491/048 ,  C07D491/107 ,  C07D498/04 ,  C07D413/14 ,  C07D487/04 ,  C07D417/14 ,  C07D409/14 ,  C07B59/00 ,  A61P25/08

CPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D495/04 ,  C07D513/04 ,  C07D471/04 ,  C07D491/048 ,  C07D491/107 ,  C07D498/04 ,  C07D413/14 ,  C07D487/04 ,  C07D417/14 ,  C07D409/14 ,  C07B59/002 ,  A61P25/08 ,  C07B2200/05

摘要： The present disclosure is directed to compounds of Formula (1):




wherein m, n, Y, R1, R2, R3, R4 and R5 are each as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of Formula (I), as described herein, which are useful as voltage-gated potassium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.